Peptides DB
Research-centric peptide and protocol reference hub
Study 29 of 29SS-31 literaturebiorxiv-preprint · RCT2026

Statistical analysis plan for the ‘Pharyngeal electrical stimulation for acute stroke dysphagia trial’ (PhEAST) (ISRCTN98886991)

The PhEAST trial is investigating pharyngeal electrical stimulation for dysphagia in stroke patients, but results are not yet available.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
2
Preclinical
20
Observational
0
Open-label
3
Randomised · this one
4
Reviews

Summary and findings

The study presents a statistical analysis plan for the PhEAST trial, which investigates pharyngeal electrical stimulation (PES) in 650 participants with tube-dependent post-stroke dysphagia. Participants are randomized to receive PES or no PES in addition to standard care, with PES administered daily for 6 days. The primary outcome is the dysphagia severity rating scale (DSR.S) assessed at days 14 and 90.

How much of this paper we could read: partial text (0.50). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>ABSTRACT</h4> <h4>Introduction</h4> Post stroke dysphagia is common, associated with poor functional outcome and lacks treatment strategies beyond behaviour therapies delivered by speech & language therapists. Here, we present the statistical analysis plan for the ongoing pharyngeal electrical stimulation for acute stroke dysphagia trial (PhEAST). PES is a candidate treatment for dysphagia present in non-ventilated stroke patients. <h4>Methods</h4> PhEAST is an investigator-initiated international prospective randomised open-label blinded-endpoint phase-4 superiority trial involving 650 participants with tube-dependent post-stroke dysphagia. Consenting patients are randomised to PES versus no PES given on top of standard care with PES given daily for 6 days. The primary outcome is the dysphagia severity rating scale (DSR.S), a measure of swallowing impairment, made at days 14 and 90 and analysed using repeated measures regression. <h4>Conclusion</h4> We present the statistical analysis plan for the main analyses based on data up to day 90 along with planned secondary analyses including presentation of baseline data, health economics, cognition and extended follow-up to 12 months.

Elsewhere in the SS-31 corpus

AUse of nicotine replacement therapy to reduce children’s exposure to second-hand smoke in the home: Findings of a pilot randomised controlled trial conducted in Scotlandbiorxiv-preprint · 2026 · Median PM 2.5 concentrations reduced in the intervention group by -36μg/m 3.HumanACardiovascular and autonomic responses to transcutaneous spinal cord stimulation combined with activity-based therapy after chronic spinal cord injury: An exploratory study from the MACHINE trialbiorxiv-preprint · 2026 · Not reported in abstract.HumanBOptimising the prevention, detection and management of diabetes distress in adults with type 1 diabetes: Feasibility study protocol (D-stress feasibility study)biorxiv-preprint · 2026 · Not reported in abstract.HumanBEpidemiology of frailty, multimorbidity, and disability: a cross-sectional study of mid-aged and older adults in The Gambia, Zimbabwe and South Africabiorxiv-preprint · 2026 · Overall mean HRQoL utility score was 0.829 ± 0.107.HumanDParent-mediated interventions versus usual care in children with autism: A systematic review with meta-analysis and Trial Sequential Analysisbiorxiv-preprint · 2026 · MD = −0.88; 95% confidence interval −2.92 to 1.15; p = 0.05, 4 trials, N = 353, low certainty.reviewBClassical driver mutations are not associated with metachronous lesion risk in patients undergoing post-polypectomy surveillance following removal of conventional adenomas in a bowel screening settingbiorxiv-preprint · 2026 · Mutation frequency in index adenomas was not associated with metachronous lesions (p=0.901).Human